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Pharmacokinetics of gentamicin during peritoneal dialysis in
children. The pharmacokinetics of gentamicin were examined on
two occasions using intravenous and intraperitoneal routes in five
children undergoing intermittent peritoneal dialysis for chronic
renal failure. Serum, urine and dialysis fluid (DF) were assayed
microbiologically for gentamicin and the data were subjected to
computer analysis using equations evolved for a two-compartment
model which considered the bi-directional flux of the drug. Follow-
ing i.v. injection of I mg/kg of gentamicin, the apparent volume of
distribution averaged 23% (range, 13 to 36%) of body wt (similar to
normal), the mean half-life was 21 hr (range, 9 to 37 hr; normal, 2
hr) and the peritoneal clearance averaged 4.0 mI/mm/rn2 (range,
1.2 to 7.0 ml/min/m2). During peritoneal administration of gen-
tamicin (15 mg/liter of DF, 0.7 liters/m2 administered in each cycle
over 9 to 12 cycles), serum concentrations increased towards ex-
trapolated steady-state levels which averaged 42% (range, 25 to
68%) of DF concentrations. The mean renal clearance of gen-
tamicin was only 1.6 mI/mm/rn2 while total body clearance ranged
from 2.3 to 8.0 mI/mm/rn2, mostly occurring by a variable degree
of dialysance. Peritoneal clearances and half-lives of gentamicin
were similar in each patient following either treatment mode. The
appreciable variability in gentamicin pharmacokinetics among
adolescent patients with renal insufficiency necessitates dosage ad-
justments based on measurements of serum concentrations.
Pharmacocinetique de Ia gentamycine au cours de Ia dialyse pen-
tonéale chez I'enfanL La pharmacocinetique de Ia gentamycine a
êté étudiée a deux reprises en utilisant les voies d'adminstration
intra-veineuse et intrapéritonéale chez 5 enfants soumis a des
dialyses péritonéales périodiques pour insuffisance rénale chro-
nique. La gentarnycine a été dosée dans Ic serum, l'urine et Ic
liquide de dialyse et les résultats ont été traités en utilisant les
equations d'un modèle a deux compartiments qui prend en compte
les flux bi-directionnels de Ia drogue. Après l'injection iv. de I
mg/kg de gentamycine Ic volume apparent de distribution est en
moyenne de 23% (13 a 36) du poids corporel, (valeur similaire a Ia
normale), Ia demie vie moyenne de 21 heures (9 a 37) alores qu'elle
est de 2 heures normalement et Ia clearance péritonéale est en
moyenne de 4,0 ml/min/m2 (1,2 a 7,0). Au cours de
l'administration péritonéale de gentamycine (15mg/I de liquide de
dialyse, 0,7 l/m2 a chaque cycle, 9 a 12 cycles) Ia concentration
sérique augmente vers un plateau, calculé par extrapolation, de
42% (25 a 68) de Ia concentration dans Ic liquide de dialyse. La
clearance rénale moyenne de Ia gentamycine Ctait de 1,6
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ml/min/m2 alors que Ia clearance totale allait de 2,3 a 8,0
ml/min/m2, surtout liée a un degré variable de dialysance. Les
clearandes peritonéales et les demies vies de Ia gentamycine étaient
semblables chez le même malade après l'administration intra-vei-
neuse ou intra-péritonéale. La variabilité importante de Ia pharma-
cocinétique de Ia gentamycine chez les malades adolescents atteints
d'insuffisance rénale nécessite des ajustements de posologie fondés
sur Ia determination des concentrations sériques.
Gentamicin is frequently used for treatment of
gram-negative sepsis. In general, the drug has a nar-
row therapeutic range and optimum antimicrobial
treatment involves maintaining peak serum concen-
trations in the range of 8 to 12 mg/liter [1]. The
pharmacokinetics of this antibiotic have been studied
in neonates [2], in infants and children [3], in adults
with various degrees of renal impairment [4, 5] and in
adults undergoing hemodialysis [6, 7] and peritoneal
dialysis [8—10]. These studies have provided reason-
able guidelines for the clinical use of gentamicin in
patients with various pathophysiologic conditions.
The major purpose of this study was to character-
ize the pharmacokinetics of gentamicin in typical pe-
diatric patients undergoing intermittent peritoneal
dialysis. A second purpose, however, was to devise
an experimental approach to quantitating the bi-
directional flux of drugs across the peritoneum. This
would improve the control of gentamicin plasma con-
centrations when the drug is injected i.v., i.p. or by
both routes of administration.
Methods
Patient studies. Five pediatric patients (Table I)
undergoing maintenance peritoneal dialysis for
chronic renal failure were studied on two occasions.
Informed consent to participate in the study was
obtained from the patients and their parents. No
patient was clinically septic or had received any anti-
biotics during the previous three days.
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Table 1. Pathophysiologic characteristics of the patients
Patient
No. Sex
Age
yr
Weights
kg
Height
cm
Surfacea
area
m' Diagnoses
I
2
3
4
5
M
F
M
M
F
14.2
15.0
8.2
15.0
13.0
55.3, 55.2
45.3, 44.1
18.3, 18.1
47.0,41.6
17.0,16.3
175
155
112
168
113
1.64, 1.64
1.41, 1.39
0.77, 0.76
1.48, 1.39
0.74, 0.73
Chronic sclerosing glomerulonephritis
Familial nephritis
Obstructiveuropathy
Obstructive uropathy
Cystinosis
Va1ues refer to i.v. and peritoneal dose studies, respectively .
Peritoneal dialysis was performed using Dianeal
solution (Travenol Laboratories) over a period of
approximately 48 hr. Each exchange consisted of
about 0.7 liters of fluid per square meter of body
surface area with an overall dialysis time of 0.75 to
1.5 hr per exchange. The clinical procedure used for
peritoneal dialysis of children has been described pre-
viously [11].
Cross-over studies were performed with each pa-
tient: administration of gentamicin by i.v. and pen-
toneal (PD) routes. For the i.v. study, a dose of I
mg/kg of gentamicin was injected over a two-minute
period at the beginning of the fourth exchange. The
penitoneal dosage consisted of administration of 15
mg/liter of gentamicin during 9 to 12 dialysis cycles,
beginning with the fourth exchange. Aliquots from
selected bottles of dialysis fluid were saved for meas-
urement of the initial gentamicin concentrations. Fol-
lowing each exchange, all dialysis fluid was collected
in a volumetric cylinder, mixed well, the volume re-
corded and a portion was saved for analysis. Blood
samples were obtained at the midpoint of each
dialysis exchange during the early part of the study
and at every fourth exchange after 16 hr of dialysis.
Blank specimens were also collected prior to adminis-
tration of the antibiotic. All urine specimens from the
patients were saved for analysis.
Assays. Gentamicin concentrations were measured
microbiologically [12] using Bacillus subtilis as the
test organism. Known concentrations of antibiotic
were added either to water or to outflow dialysis fluid
which served as standard curves for assaying serum
and urine or dialysis fluid concentrations of the anti-
biotic, respectively. Preliminary studies showed iden-
tical bioassay data when gentamicin is added either to
water or serum. Stability experiments, consisting of
preparation of a fresh solution of 15 mg/liter of
gentamicin in dialysis fluid and microbiologic analy-
sis of the solution at various times thereafter, showed
no changes in gentamicin concentrations for six
hours at 37°C and for four weeks at 4°C. Samples
from individual patients were stored at 0°C and as-
sayed at one time. Creatinine concentrations in se-
rum, urine and dialysis fluid were assayed using the
colonimetric procedure of Heinegard and Tiderstrom
[13].
Pharmacokinelic analysis. Kinetic relationships to
describe the process of peritoneal dialysis for the
purpose of interpreting results and making quan-
titative comparisons among compounds have been
provided by Boen [141, McLean et al [15] and
Henderson and Nolph [16]. These relationships are
largely based on principles of passive diffusion be-
tween plasma and dialysis fluid. More recently, Babb
et al [171 included the concept of ultrafiltration in
developing equations to characterize mass transfer of
"middle molecules." The major advantage of the lat-
ter report is the consideration of bi-directional flux of
drug across the peritoneum with solvent drag con-
tributing to drug movement from plasma into dialysis
fluid. The present pharmacokinetic methodology,
though not comprehensive, utilizes clearance con-
cepts in characterizing the peritoneal transfer kinetics
of gentamicin according to the model shown in Fig.
1. Equations for solution of the model and exam-
ination of experimental data are presented in the
Appendix.
Numerical values for the various parameters of
Fig. I were obtained by nonlinear, least-squares re-
gression using the digital computer program, NON-
LIN [181. Appropriate subroutines were written to
incorporate the equations for i.v. or peritoneal ad-
ministration of gentamicin. The serum and dialysis
were examined simultaneously and a weighting func-
tion was employed which imparts equal weight to all
data points.
Results
Intravenous dosage. The time-course of serum and
dialysis fluid concentrations of gentamicin after i.v.
administration of the antibiotic to one of the patients
(patient 2) is shown in Fig. 2. Although the data are
sometimes slightly erratic owing to analytical and
dialysis rate variabilities, the pharmacokinetic model
yields a reasonable characterization of the overall dis-
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Fig. 1. Pharmacokinetic scheme describing the distribution and
elimination of a drug during peritoneal dialysis. C and Cd are drug
concentrations in plasma and dialysis fluid; YB and V0 are volumes
of the body and dialysis fluid compartments; Clx, CIM and Cl0 are
renal, metabolic and peritoneal clearances; and ClPd and Cl5 are
transfer clearances between plasma and dialysis fluid; (all in respec-
tive order). The solid arrows represent continuous drug transport
processes while the interrupted arrows represent the intermittant
draining and replacing of dialysis fluid in the peritoneum.
position of gentamicin. The pharmacokinetic indexes
which can be generated from such data are listed in
Table 2. For this analysis, the data were first examined
to obtain values for the plasma concentration vs. time
area (by trapezoidal integration) and the mean volume of
dialysis fluid recovered (V0). Computer-generated
values were then obtained for the apparent volume of
distribution (VB) and the transfer clearances (Cl10,
Clpd) by least-squares iteration of equations 6 and 7.
Subsequently, the body clearance (Cl8, equation 10),
the beta half-life (t11, equation 12), and the net
peritoneal clearance (Cl0, equation 11) were calcu-
lated. In addition, the renal and peritoneal clearances
of creatinine were found using equations 9 and 11.
The data were analyzed with and without including
the value of C1M as a variable (equation 2). Because
initial computer iteration revealed CIM to be in-
consequential, it was subsequently set equal to zero.
This is consistent with data in the literature that
gentamicin is not subject to biotransformation [7].
Confirmation of this was noted, however, in finding
that independent calculation of body clearance by
equation 10 and by adding renal and peritoneal clear-
ances (Cl8 = C1R + Cl0) yielded essentially identical
values leaving C1M a negligible parameter.
The apparent volumes of distribution of genta-
micin in the five children are listed in Table 2. The
Table 2. Pharmacokinetic indexes of gentamicin after iv. administration
Patient Dose
Volume of
distribution
Half
life
Plasma
cone-time
area
Clearances, mi/minIm2
Gentamicin Creatinine
Transfer, Transfer,
No. mg liters (% of body WI) hr mg hr/liter Body Renal Dialysis CIPd CIdS Renal Dialysis
I 30 10.9 (19.7) 37.4 134 2.27 0.91 1.37 2.06 0.72 1.36 2.64
2 40 10.1 (22.3) 9.9 59.1 8.01 0.98 7.03 6.04 2.72 1.62 5.44
3 18 2.38(13.0) 28.5 132 2.95 1.73 1.22 13.25 4.21 2.82 3.90
4 50 16.8 (35.7) 20.6 78.6 7.16 2.20 4.96 7.43 1.66 4.76 2.90
5 16 4.06(23.9) 9.3 52.6 6.85 1.58 5.27 5.49 2.89 1.55 5.59
Mean 22.9 21.1 5.45 1.48 3.97 6.85 2.44 2.42 4.09
(so) ( 8.3) (12.1) (2.64) (0.54) (2.57) (4.08) (1.32) (1.43) (1.38)
Sourcea LS-6 D-l2 D-10 D-9 D-ll LS-6 LS-6 D-9 D-ll
Source of values is either least-square iteration (LS) or direct (D) computation using the indicated equation.
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Fig. 2. Serum (.) and dialysis fluid (o) concentrations of gentamicin
as a function of time after iv. administration of 40 mg of the
antibiotic to subject 2 (Tables 1—3). The lines were fitted to serum and
dialysis fluid data by least-squares iteration of equations 6 and 7,
respectively.
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range of values (13 to 36% of body wt) is comparable
to data obtained in adults with chronic renal failure
[7]. Except for the appreciable variability which in-
cludes one child with an unusually low VB value,
there is essentially no difference in the mean volume
of distribution between children (12 liters) and adults
(14 liters) when the data are normalized for body
surface area (per 1.73 m2). There was no apparent
reason for the unusually large range of YB values in
these adolescent patients.
Several clearance values were calculated (Table 2).
The renal clearance of gentamicin was, as expected in
these azotemic patients, extremely low and averaged
1.48 mI/mm/rn2. The renal clearance of gentamicin
was about 68% of the endogenous creatinine clear-
ance. A similar ratio had been found in other studies
in adults [5, 7]. Gentamicin is excreted largely by
glomerular filtration and this difference is probably
due to some degree of tubular secretion of creati-
nine.
The elimination clearances of gentamicin, normal-
ized for body surface area, are shown in Fig. 3. The
appreciable variability in the body clearance of the
antibiotic can be seen to be due largely to the wide
range of peritoneal clearance values. The latter had
a seven-fold range of 1.22 to 7.03 ml/min/m2 un-
der very similar dialysis conditions in this group of
patients. Such variability in dialysis rate, coupled
with the appreciable differences in volume of distri-
bution among the patients, also accounts for the dis-
parent beta half-life values: a range of 9.3 to 37.4 hr
can be noted in Table 2. There was no relationship
between the dialysance of gentamicin and creatinine.
The gentamicin:creatinine dialysance ratio ranged
from 0.31 to 1.71 (Table 2). This variability precludes
use of creatinine measurements to predict the rate of
loss of gentamicin in the dialysis fluid.
The transfer clearances of gentamicin between
plasma and dialysis fluid are listed in Table 2. The
major characteristics of these data are the highly
variable clearances among the patients and the rela-
tive magnitude of the ClPd:CLJP values, The latter
ratios are greater than unity (mean = 2.92) which
indicates that movement of the drug from plasma
into dialysis fluid occurs at a much faster rate than
the reverse transfer process.
Peritoneal dosage. The time-course of serum and
dialysis fluid concentrations of gentamicin during
and after peritoneal administration of the antibiotic
to one of the patients (patient 5, Tables 1-3) is shown
in Fig. 4. It can be noted from the graph that the
peritoneal absorption of gentamicin is quite slow: the
concentration in the dialysis fluid decreased only
slightly while the serum concentrations increase very
0 --
1 2 3 4 5
Patient No.
Fig. 3. Total body clearances (full bars), renal clearances (hatched
bars), and peritoneal clearances (open bars) of gentamicin in the
peritoneal dialysis patients.
gradually. The fall in the initial dialysis fluid concen-
trations of gentamicin is partly due to a dilution
effect since the dialysis procedure leads to loss of
body fluid in the patients. The mean volume of
dialysis fluid recovered showed increases of 4 to 8%.
Upon discontinuation of direct addition of the drug
to the dialysis fluid, the decline in both plasma and
dialysis fluid concentrations largely reflects the elimi-
nation rate of the antibiotic. However, there is an
early phase where the residual drug in the perito-
neum mixes with the fresh solution to yield higher
gentamicin concentrations in the dialysis fluid than
would be expected if complete wash-out occurred.
This effect can be seen over the five- to seven-hour
period in Fig. 5 and necessitated use of the residual
correction factor in equation 14.
The curves in Fig. 4 represent the results of com-
puter least-squares iteration of equations 6, 13 and
14. Fit to these data was excellent and yielded values
for the indexes ClPd, CL0 and FR. Prior to such itera-
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Table 3. Pharmacokinetic indexes of gentamicin after peritoneal administration
Meana Steady- Plasma:DF
volume of Drug Duration Plasma state equilibration Clearances, mi/mm/rn2
Patient
dialysis
fluid
dialysis
cycles
of drug
administration
cone-time
area
plasma
conc.
ratio Half-
life Gentarnicin, Creatinine, Creatinine,
No. liters N hr mg hr/liter mg/liter i.v. PD hr renal renal dialysis
1 1.081 9 16.1 184 10.2 0.35 0.68 44.4 0.13 0.37 2.52
2 1.073 12 11.3 82.4 6.98 0.45 0.46 18.6 0.96 1.65 4.55
3 0.536 9 7.3 48.9 6.26 0.32 0.42 17.9 1.74 2.42 3.22
4 1.078 ii 9.7 39.8 3.76 0.22 0.25 7.4 4.49 3.68 3.67
5 0.520 11 6.8 32.4 7.32 0.53 0.49 10.7 1.14 1.30 7.36
Mean 1.69 1.88 4.26
(SD) (1.67) (1.25) (1.88)
Source5 D-15 D-16 D-16 D-12 D-9 D-9 D-ll
Volume administered was 0.7 liter/rn2.
b Source of value (key in Table 2).
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Fig. 4. Serum (1) and dialysis fluid (A) concentrations of gen-
tamicin as a function of time during and after the course of adminis-
tration of the antibiotic in the dialysis fluid to subject 5. The lines
were fitted to the data by computer least-squares iteration of equa-
tions 13, 6 and 14.
tion, however, the equations in the program were
supplied values of CIR (calculated from the area and
urinary recovery using equation 9), V (obtained
from the i.v. data) and V0 (measured directly). In
turn, values of C and RPfd were generated using
equations 16 and 17 and the beta half-life was calcu-
lated with equation 12. The values of some of these
indexes are listed in Table 3.
The same type of variability occurs in the pharma-
Fig. 5. Serum concentrations of gentamicin as a function of time
during and after administration of the antibiotic in dialysis fluid to
subjects 2 () and / (•). The solid lines were fitted to equations 13
and 6 while the broken line shows the extrapolated serum concentra-
lions expected (equations 13 and 15) if gentamicin was continually
added to dialysis fluid.
cokinetics of gentamicin after both peritoneal and i.v.
administration of the drug. In particular, the renal
clearance and dialysance of creatinine and the renal
clearance of gentamicin are usually similar for each
patient in the crossover studies (Tables 2 and 3).
Of major importance is the fact that the rate of
elimination of gentamicin is similar on the two study
occasions as shown by the beta half-life values. For
example, the patients with the shortest and longest
half-lives had nearly identical values in the crossover
studies (about 10 and 40 hr, respectively).
A basic clinical question in the use of many drugs,
especially antibiotics, concerns the ultimate plasma:
dialysis fluid equilibrium ratio established upon con-
tinual peritoneal administration of an agent. For
example, Fig. 5 shows actual serum concentration vs.
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time data measured in two patients along with the
extrapolated effect of continued addition of the drug
to dialysis fluid. These data, as well as the values
in Table 3, indicate that plasma concentrations will
equilibrate at an average of 6.3 mg/liter, well below
the 15 mg/liter concentration added to dialysis fluid.
The calculated equilibrium ratios are listed in Table 3
and graphed in Fig. 6 for the five patients. The advan-
tage of using the evolved pharmacokinetic model is
that RP/d values can be calculated and compared after
both i.v. and peritoneal administration of the drug.
These ratios are highly variable among the patients
with a range of 0.22 to 0.68 (mean = 0.42), but four
of the five patients showed nearly identical ratios in
their crossover studies. Some of the present crossover
studies were carried out as long as six months apart.
These data, along with the similar beta half-life
values in the crossover studies, suggest that the trans-
fer characteristics of the peritoneum remain relatively
constant within this time frame in the individual pa-
tients.
Discussion
Pharmacokinetic relationships have been evolved
to quantitate the distribution and clearance charac-
teristics of some drugs during peritoneal dialysis. The
primary advantages of these relationships are that
they allow characterization of drug disposition after
either i.v. or peritoneal administration of the drug
and clearance constants can be calculated for move-
ment of drug in both directions across the per-
itoneum. This yields a more complete description of
the process of peritoneal dialysis than use of only the
peritoneal clearance value. The latter reflects the net
removal rate of drug under specified dialysis condi-
tions while the proposed pharmacokinetic relation-
ships provide separate incorporation of indexes such
as volume of dialysis fluid and duration of the dialysis
cycle, factors which directly affect dialysis rate. Since
most of the major indexes of the system are ac-
counted for, the proposed equations can be used for
extrapolation. This advantage is exemplified in Fig. 6
where the plasma:dialysis fluid equilibrium ratio was
predicted for the crossover studies with gentamicin.
The evolved equations do not have general appli-
cability. Their major limitation is with respect to the
number of body compartments. A two-compartment
body model (plasma and dialysis fluid) was adequate
for gentamicin. This is consistent with previous stud-
ies [7] which have found a one-compartment model
adequate for gentamicin under nonperitoneal dialysis
conditions. Other drugs may require a more com-
plicated mammalary kinetic system with multiple
body compartments and other pathways of elimina-
tion accounting for disposition of the drug. However,
the simple principle of applying unequal forward and
reverse clearance constants between plasma and
dialysis fluid should be generally applicable for all
drugs. This approach was introduced by Babb et al
[17], who describe a solvent drag process from
plasma into dialysis fluid which probably also ac-
counts for our finding that ClPd > CldP (Table 3).
The peritoneal clearance of gentamicin in the five
pediatric patients averaged about 4 mI/mm/rn2 with
a ten-fold range of values. Overall, the dialytic kinet-
ics of the antibiotic are similar in children and adults.
For example, Gray [8] found clearance values of 8
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Fig. 6. Expected plasma:dialysis fluid equilibrium ratio (equation
16) expected upon continuous peritoneal administration of gen-
tamicin to the five patients. Values were calculated from data ob-
tained after iv. and peritoneal (PD) administration of gentamicin.
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and 19 mi/mm in two adult patients while Smithivas
et al [9J found a range of 5 to 12 mi/mm in four
patients. The latter study also showed a range of half-
lives of 5 to 28 hr (mean, 15 hr) for gentamicin in
azotemic patients. Similar peritoneal clearance values
of 6 to 11 mi/rn in have been found by Atkins et al
[19] for kanamycin, an aminoglycoside antibiotic
with pharmacokinetic properties nearly identical to
those of gentamicin [7]. In addition, kanamycin
reaches an equilibrium serum concentration of ap-
proximately 50% of the dialysate inflow concentra-
tion, similar to the mean value of 42% calculated for
gentamicin in the present study (Fig. 6). For the age
range of the patients of this study (8 to 15 yr), it
appears that the pharmacokinetics of gentamicin in
azotemic children undergoing peritoneal dialysis are
similar to those of gentamicin and kanamycin in sim-
ilarly afflicted adult patients.
The variability in the pharmacokinetics of gen-
tamicin during peritoneal dialysis and the lack of
correlation of peritoneal clearance to an easily meas-
ured endogenous compound such as creatinine in-
dicates that serum concentrations of the antibiotic
must be monitored in septic patients treated with
aminoglycoside antibiotics in order to maintain ther-
apeutic and nontoxic dosages. However, the data
found in the present study can be used to provide
some approximate guidelines for the clinical use of
gentamicin in children.
Appendix
The data were anlyzed using the simplest possible
pharmacokinetic model (Fig. I) which permitted ade-
quate characterization of the time-course (t) of serum
(Cr) and dialysis fluid (Cd) concentrations of gen-
tamicin while allowing generation of the clearances
between the plasma and dialysis fluid compartments
(ClPd and Cldp) as well as the renal (CIR) and net
dialytic (CID) clearance of the antibiotic. The appar-
ent volume of distribution of gentamicin in the body
is VB while VD is the volume of dialysis fluid in the
peritoneum.
Intravenous dosage. The rate of change of serum
concentrations of drug (Ca) following i.v. injection of
the dose (D0) can be described by the following differ-
ential equation:
VB' Cld•Cd — CiA'C
CIA = CIR + C1Pd + CIM
= DO/VB
B1 = C1A/VB,
B2 = Cldp/VB,
B3 = CIPd/VD,
B4 = Cldp/VD,
R = B1 + B2,
S = B1 B4 + B2 B3,
(3)
(4)
(8a)
(8b)
(8c)
(8d)
(8e)
(8f)
(8g)
(10)
The rate of change of dialysis fluid concentration (Cd)
is
— CldC Cl4C4.
The initial conditions (C°, Cd°) of the system are
and ( 0 —
The analytic solutions to these differential equations
are as follows:
C1• (B. — e + c!L_.. e 'At (6)a—f
and
C •B3 —oAt
—e ) (7)
where is the plasma concentration of gentamicin
at the beginning of each dialysis cycle and t is the
time interval of the entire dialysis cycle (including
inflow, retention and outflow time). The other sym-
bols are defined as
where
a = /2 (R +\/R — 4 . S).
Additional indexes which can be calculated to de-
scribe drug disposition include the renal clearance
obtained from the following relationship:
CIR = xi/j'T C9•dt (9)
where XU is the total amount of drug excreted in
urine over the time interval from 0 to I and the
denominator is the area under the serum concentra-
tion vs. time curve over the same time interval. The
body clearance (CIB) is also a model-independent
index which can be calculated from the following:
(1)
C1B D0/ j C•dt + C*/
where C is the concentration of the last serum
(2) sample collected.
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Cld• YDC1D = Cld
The mean peritoneal clearance (C1D) can be ob- which is the time infinity limit of equation 13. Sim-
tamed from the following: ilarly, the equilibrium ratio between plasma and
/ T dialysis fluid (Rp,d) expected upon continued admin-Cl = XI / J C9dt (11) istration of drug can be obtained from the following:/ 0
where XDJ' is the total amount of drug removed in RP,d = CldP/(CIPO + Cl + CIM). (16)
the dialysis fluid over the time interal 0 to T. It must This relationship applies to both routes of adminis-
be emphasized that C1D is a hybrid, time-average tration of the drug.
value which is dependent on the relative values of Factors affecting dialysance. Further examination
ClPd and CLjr, the retention time of the dialysis fluid of the evolved model allows the factors which deter-
and the volume of the dialysis fluid (see equation 18). mine the peritoneal clearance to be summarized into
However, it is highly useful because it represents the a single expression. For this purpose, equation 11 can
proportionality factor between drug concentrations be rewritten as
in the plasma and the amount removed with the —
dialysis fluid. VD f cd.dt/f C•dt. (17)The beta half-life was calculated from C1D
Integration of equation 7 for the numerator and
tl/Z = 0.693/3. (12) equation 6 for the denominator ultimately yields the
Peritoneal administration. The loss of gentamicin following relationship:
from the dialysis fluid during peritoneal administra-
tion of the antibiotic was relatively small. Thus, the (18)
gentamicin content of the dialysis fluid can be as-
sumed to be constant at a mean concentration of Thus, the peritoneal clearance is a function of the bi-
Cj. Under such conditions, the solution to equation directional transfer clearances, the volume of dialysis
1 is as follows: fluid instilled into the peritoneum and the duration
of the dialysis cycle. Equation 18 reflects peritoneal
B2C clearance over each time period; the mean or time-(1 — eB •t) (13)CV B1 average dialysance can be written as
where B1 and B2 are defined in equations 8a and 8b —
= Cld• VDC1D (19)and C' is calculated from the average of the initial Cld9 T
and final concentrations of gentamicin in the dialysis where VD is the total volume of dialysis solution
fluid. This relationship can be used to characterize used and T is the duration of the entire (continuous)
the time-course of increase in plasma gentamicin con- dialysis procedure. These equations do not account
centrations during peritoneal influx of the drug. Fol- for the possibility of changes in the transfer clear-
lowing cessation of this mode of administration, the ances with use of various VD values.
decline in plasma concentrations can be quantitated
with equation 6 while the dialysis fluid concentrations
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